A novel bis(L-carnitinato)Zn(II) complex, Zn(car) 2 Cl 2 , was prepared, and its insulinomimetic and antidiabetic activities were examined. The complex showed a tendency to lower the high blood glucose levels of KK-A y mice with type 2 diabetes mellitus when given by oral administration at a dose of 20 mg Zn/kg body weight for 16 d. In addition, the complex improved glucose tolerance ability when examined by the oral glucose tolerance test (1 g glucose/kg body weight).
Recently, both Zn(II) ion and several Zn(II) complexes have been found to have insulinomimetic activity. 1) We reported that Zn(II) complexes with nicotinamide, maltol, amino acids, picolinic acid, picolinamide, and their derivatives have high insulinomimetic activities in in vitro and in vivo studies. [2] [3] [4] [5] [6] [7] However, these complexes were effective in showing the lowering effect of blood glucose by daily intraperitonial injections to type 2 diabetes mellitus. When aiming at the clinical use of the complexes, it is essentially important to find complexes that are effective on oral administration. During the investigation for developing orally active insulinomimetic Zn(II) complexes, we found that a Zn(II) complex with L-carnitine ((R)-3-hydroxy-4-(trimethylammonio)butanoate : car) improves type 2 diabetes mellitus in mice when administered orally.
L-Carnitine is known to be a vitamin-like nutrient (Vitamin B T ) found in the heart, brain, and skeletal muscles. [8] [9] [10] It was reported that L-carnitine is incorporated in the body through the carnitine transporter. 11, 12) Its primary physiological role is to transport fatty acids across the cell wall into the mitochondria to provide the heart and skeletal cells with energy. 13) In in vitro studies, it was reported that L-carnitine reverses much of the damage inflicted on the brain by free radicals.
14) L-Carnitine has been used as a supplement which maintains physical stamina and promotes weight loss. 15) On the other hand, the body uses L-carnitine to produce the enzyme, acetyl-L-carnitine transferase, which boosts choline metabolism and releases acetylcholine in the brain. 16, 17) We synthesized the complex, Zn(car) 2 2 Cl 2 ). Therefore, we estimated the structure of Zn(car) 2 Cl 2 as shown in Fig. 1 .
The insulinomimetic activity of the complex was evaluated by using the isolated rat adipocytes treated with epinephrine in terms of the inhibition of free fatty acid release. 18, 19) The inhibitory effect of Zn(car) 2 Cl 2 was compared with those of VOSO 4 and ZnSO 4 as positive controls (Fig. 2) .
The effects of the three compounds were dose-dependent in the concentration range of 10 Ϫ4 -10 Ϫ3 M. From these results, the apparent IC 50 value, a 50% inhibitory concentration of the FFA released in each complex, was estimated to be 0.80Ϯ0.05 mM for Zn(car) 2 Cl 2 . Zn(car) 2 Cl 2 was found to be more active than VOSO 4 (IC 50 ϭ1.00Ϯ0.08 mM) and to have almost the same activity to that of ZnSO 4 (IC 50 ϭ0.81Ϯ0.10 mM). In our previous research, if IC 50 value of the VO compounds were equal to or less than 1.00 mM, the compounds showed antidiabetic activity by oral administration. 1) In this study, we tested the Zn(II) complex by oral administration.
We evaluated the in vivo blood glucose lowering effect of Zn(car) 2 Cl 2 in KK-A y mice (22 weeks old: CREA Japan Inc., Tokyo) with type 2 diabetes mellitus. In this study, we used KK-A y mice at the age of 22 weeks old because the blood glucose levels of old diabetes patients were reduced by administration of bovine prostate powder supplemented with Zn. 20) They received oral administration of the complex daily at about 10:00 a.m. for 16 d. Blood samples were obtained from the mouse-tail vein, and the glucose levels were measured with a Glucocard (Arkray, Kyoto). The body weights of KK-A y mice, which were allowed free access to solid food (CREA Japan Inc.) and tap water, were measured daily during the administration of Zn(car) 2 Cl 2 . The intakes of solid food and drinking water for each mouse were checked daily throughout the experiments. When the mice were given Zn(car) 2 Cl 2 at a dose of 20 mg Zn/kg body weight, they had a tendency to lower the blood glucose levels during the complex administration for 16 d (Fig. 3 left) . The body weight of the KK-A y mice in each group decreased slightly (Fig. 3  right) . Also, due to the improvement of the blood glucose level of the KK-A y mice treated with the Zn(car) 2 Cl 2 by daily oral administrations at the dose of 20 mg Zn/kg for 16 d, the KK-A y mice received the oral glucose tolerance test. As shown in Fig. 4 , the blood glucose levels of the KK-A y mice treated with L-carnitine were elevated to the maximum (520 mg/dlϭ28.9 mM) at 30 min after the glucose administration, and then gently decreased. In contrast, the blood glucose levels of the KK-A y mice treated with Zn(car) 2 Cl 2 were also elevated (304 mg/dlϭ16.9 mM) for 30 min, however, they were obviously lowered when compared with those of the KK-A y mice treated with L-carnitine. The area under the curves (AUC ) of the glucose level in the blood were calculated from the data in Fig. 4 , being estimated to be 690Ϯ154, 789Ϯ184 and 431Ϯ216* (mg/dl h) for the control KK-A y mice, KK-A y mice treated with L-carnitine, and KK-A y mice treated with Zn(car) 2 Cl 2 , respectively (* significance at pϽ0.05 vs. the KK-A y mice treated with L-carnitine (by Student's t-test)). These results strongly indicated that the treatment of Zn(car) 2 Cl 2 improves type 2 diabetes mellitus in KK-A y mice by oral administration.
The proposed Zn(car) 2 Cl 2 is assumed to be incorporated in the body through the carnitine transporter. Previously, Shisheva et al. have reported that a high dose of ZnCl 2 (210 mg Zn/kg body weight) stimulates the glucose uptake in rat adipocytes and reduces blood glucose concentration as much as 50% when was given orally to STZ rats. 21) In contrast, Zn(car) 2 Cl 2 at a low dose (20 mg Zn/kg body weight) was effective in lowing the blood glucose concentration orally administered.
In conclusion, Zn(car) 2 Cl 2 has been found to have the in vitro insuinomimetic activity and in vivo blood glucose lowering effect, the improvement of the diabetes being supported by the results of the glucose tolerance test. The present result is the first example for the orally active Zn(II) complex. A detailed study about the mechanism of Zn(car) 2 Cl 2 is now under way. The obtained results will be useful when they are clinically used on type 2 diabetes mellitus in the future. Vol. 51, No. 2 
